Introduction
T h e fibroblast growth factors (FGFs), a large protein family with 16 documented members, regulate cell proliferation and differentiation [ 11. FGFs activate signal transduction by binding to their high affinity receptors, FGFRs, a family of cell surface tyrosine kinases [Z] . Four related FGFR genes have been cloned, but many different protein products can be produced by alternative mRNA splicing [2] . The extracellular portion of the receptors, responsible for binding FGF, is composed of three immunoglobulin (1g)-like domains connected by linker regions. A receptor fragment spanning the two C-terminal Ig-like domains is sufficient for interaction with the ligand [3, 4] . Heparin or heparan sulphate is necessary for biological activity, but its role in activating the FGF signalling pathway is still unclear, and its direct involvement in the FGF-FGFR interaction remains under question [5, 6] . No crystal structure is available for a FGF-FGFR complex, but several models of the extracellular region of the receptor, alone or in a complex with FGF, have been proposed [7- 111. Here we present some evidence that heparin might be an essential component of the FGF-FGFR association that leads to transduction of the signal to the inside of the cell.
Modelling of the extracellular domains of FGFR2c in complex with FGF2
We have built a model of the complex of the two C-terminal domains (IgII and IgIII) of the extracellular portion of human FGFR2 (IIIc exon) with FGF2 (basic FGF). The extracellular Ig-like domains of the FGF receptors have been predicted to belong to the I set of the immunoglobulin superfamily [12] . The model was produced by analogy with the structure of the Abbreviations used: FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; IL-lR, interleukin-1 receptor; IL-10, interleukin-lfl; GST, glutathione S-transferase; Ac, acetate. ' To whom correspondence should be addressed.
C-terminal domain of myosin light chain kinase from turkey gizzard telokin, the crystal structure of which has been published [ 131 and which is a member of the I-set immunoglobulin superfamily. Telokin was chosen because it gave the best amino acid sequence alignment with FGFR2c, with the fewest insertions or deletions. This is in agreement with the sequence analysis by Bateman and Chotia [9] . The conformation and the orientation of the linker region between the two domains of FGFR2 was modelled using the recently released crystal structure of the interleukin-1 (IL-1) receptor (IL-1R) in complex with interleukin-lp (IL-1p) [14] . IL-lR, like the FGFRs, contains three Ig-like domains in its extracellular region, and binds to a cytokine, IL-1, that belongs to the same structural superfamily as the FGFs. In particular, both IL-1R and the FGFRs contain a Pro-Xaa-Arg-Pro motif within the linker region connecting IgII and IgIII: Pro-Thr-Arg-Pro (residues 206-209) in IL-lR, Pro-His-Arg-Pro (residues 253-56) in FGFR2. This linker sequence is identical in all four FGFR proteins. The position of the FGF2, bound to a heparin tetramer, (pdb code: lbfb) [15] was based on that of IL-lB in the IL-1 receptor-11-lg structure [ 141.
Comparative modelling was performed using the automatic rule-based procedure encoded in the COMPOSER suite of programs [16, 17] . All calculations were performed on a Silicon Graphics Indigo2 workstation using COMPOSER within SYBYL (Tripos Associates Inc.). Figure 1 shows a ribbon diagram of the FGF2-FGFR2c complex. Assuming that FGF2 binds to FGFR in the same orientation as IL-lp binds to IL-1 R, the FGF2-bound-heparin molecule is positioned at the interface between the IgII domain of the receptor and the ligand. This heparin binding cleft (Figure 2 ) consists of a cluster of exposed, positively charged residues, and includes most of the basic residues that have previously been predicted to be involved for both the ligand [18] and the receptor [19] . This highly charged interface region would need to be neutralized by the polyanionic heparin in order to stabilize the FGF2-FGFR2c complex.
Reconstitution of a FGF2-FGFR2c complex
We have performed a series of experiments to determine whether it is possible to reconstitute a FGF2-FGFFQc complex in aitro from purified components by means of gel filtration chromatography, in order to produce a homogeneous ligand-receptor complex for structural studies. T o do this, human FGF2 and the extracellular region of human FGFR2c have been overexpressed in Escherirhia coli and purified to near homogeneity.
Decameric heparin oligosaccharide material 
Overexpression and purification of human FGFZ
Human FGF2 cDNA was amplified by PCR and subcloned into expression vector pGEX-4T-1 (Pharmacia). FGF2 was overexpressed in E. coli strain BL21 (DE3) as a soluble glutathione S-transferase (GST) fusion protein and purified by affinity chromatography over a heparinSepharose CL-6B column (Pharmacia). The GST tag was cleaved by thrombin digestion, and removed by binding to glutathione-Sepharose CL-6B beads (Pharmacia). T h e FGF2 protein was further purified by cation exchange chromatography over a Monos 5/5 HR column (Pharmacia).
Overexpression and purification of human FGFR2c
Human FGFR2c cDNA was amplified by PCR and a fragment of the extracellular portion of FGFR2 type IIIc spanning the two C-terminal Ig-like domains was subcloned into expression vector pET3a (Novagen). FGFR2c was overexpressed in E. coli strain BL21 (DE3)pLysS, refolded from inclusion bodies and purified by ion exchange chromatography over an SP Sepharose HR column (Pharmacia) and by affinity chromatography over a heparin-Sepharose CL-6B column (Pharmacia) . Freeze-dried heparin decamer was solubilized in MilliQ water and stored in aliquots at -80°C.
Analysis of ligand-receptor complex formation
Reconstitution of a ligand-receptor complex was monitored by gel filtration chromatography. FGF2; FGFR2c and heparin decamer were mixed in stoichiometric ratios of 2:2:1 to a final FGFUFGFFQc concentration of 120 pM, heparin decamer concentration of 60 pM, and incubated on ice for 15 min. T h e sample was then loaded onto a Superdex 200 10/30 HR column pre-equilibrated in buffer: 20 mM Tris/HCl, pH 7.5, 100 mM NaCl, 0.1 mM EDTA, and run at 0.5 ml/min on an FPLC system. Chromatographic fractions were analysed by SDS/PAGE. All experiments were performed at 4°C. Protein concentration was determined from absorbance at 280 nm using a theoretical extinction coefficient based on the aromatic amino acid content. By mixing pure, concentrated FGF2 and
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FGFR2c proteins together we were unable to detect coelution of ligand and receptor in a single peak, and the two protein molecules eluted separately. Complex formation, as inferred by coelution of FGF2 and FGFR2c, was only observed when a heparin decamer molecule was added to the protein sample (Figure 3) .
Further complexation experiments showed that the addition of MgC12 (to 25 mM), together with heparin, improved the amount of complex formation. Increased FGFR affinity for heparin in the presence of MgZc and Ca2+ has been reported previously [ 101. Indirect evidence that heparin is involved in ligand-receptor complex formation was also obtained by performing the experiment in 20 mM sodium acetate buffer at pH 5.0; in this case, ligand-receptor association was reduced. This was possibly due to partial titration of the sulphate groups of heparin and disruption of the interaction, presumably electrostatic in nature, with the predominantly basic residues on the receptor and the ligand that form the heparin binding site.
The combined evidence from comparative modelling and from biochemical studies of the FGF-FGFR interaction suggests that heparin might be needed to stabilize the ligand-receptor interaction, and that a stable ligand-receptor association might require the presence of heparin as an essential component of a FGF-FGFR-heparin ternary complex.
